Simcere Pharmaceutical Group Limited
2096
Rang in aandelen
#4480
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Aandeelprijs
$1.32
Marktkapitalisatie
$3.40B
Verandering (1 dag)
-4.51%
Verandering (1 jaar)
-19.88%
Land
CN
Handel Simcere Pharmaceutical Group Limited (2096)
Categorie
Healthcare
Operationele marge voor Simcere Pharmaceutical Group Limited (2096)
Operationele marge op October 2026 TTM: 20.94%
Volgens de meest recente financiële rapporten en aandelenkoers van Simcere Pharmaceutical Group Limited is de huidige operationele marge (TTM) 20.94%. Eind 2024 had het bedrijf een operationele marge van 12.78%.
Geschiedenis van de operationele marge van Simcere Pharmaceutical Group Limited van 2012 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 20.94% | 4.08% |
| 2025 | 20.12% | 57.43% |
| 2024 | 12.78% | 18.66% |
| 2023 | 10.77% | -21.10% |
| 2022 | 13.65% | -52.88% |
| 2021 | 28.97% | 40.90% |
| 2020 | 20.56% | -11.61% |
| 2019 | 23.26% | 11.45% |
| 2018 | 20.87% | 52.11% |
| 2017 | 13.72% | 196.33% |
| 2012 | 4.63% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -98.16% |
US
|
|
| -149.01% | -107.12% |
US
|
|
| 25.57% | -98.78% |
AU
|
|
| 28.81% | -98.62% |
NL
|
|
| 31.23% | -98.51% |
BE
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.